Member Info for pomander

The last update on the RTO was via a JM tweet - ''watch this space'' were his words from memory, but that was several months ago now. It still figures in the latest company update (Oct 2017) so if there isn't anything simmering in the background. Its very much the JM show and JG has no expertise to select phrma investmenets so he remains clear of any accountability on that front. Have you been sniffing around- you seem more positive again ?

And apparently Bignose, you also know all about feminine hygiene products in addition to your veggies! Not that I am overly concerned, but th DBc looks like going the way of so many initially crowd funded projects. JM has a fixed and floating charge over the whole shooting match, having kept it alive by sticking in a couple of million in- but its monopoly money to him. He will end up owning a dud or a deal will be struck in the US - he is rather good at that and will not wish to let down shareholders in the stable of his companies involved, but this one is not looking too rosy at the moment.

Interesting theory Matt and one that has surfaced before. - I don't have any issue with Alq posting, it is always good to be challenged and he certainly knows his onions. It is only when he goes off-piste that my suspicions are aroused as to some possible ulterior motive, but then how would posting on here serve that ? So I tke it all with a large pinch of salt.

Alq- do you have a grudge against JG for some reason, for it does come over that way given that you are not shareholder ?

Bignose - Good to hear that - MW perhaps?

I am not sure about that- I suspect JG is a very successful guy and might just dwarf those who critcism him on a combined basis.

Chris- Yes, unfortunately it does appear that there are AIM investors/traders looking to sell into any liquidity to exit. That can all change very quickly, but I always view small bio pharma stocks as a percentage game requiring a well diversified portfolio as they can fall over at any time. The old adage,'' better to travel than arrive'' often rings true in this sector.

Top sniffing- must be the supersonics kicking in. Get the silo ready !

Alq- you do tend to paint a picture of Jamie Gibson rummaging around, all alone in his office trying to complete various forms for the FDA submission but never being able to get past the first box due to an inability to even spell Fortacin correctly. RP have made some dumb mistakes, but surely the FDA submission will be firmly in the hands of experienced US based consultants.

Alq- EMA were satisfied, so I will take that as a good steer in conjunction with the compounds involved and the condition. I accept you maybe correct and that could be holding back potential US partners. Cheerio

Alq The need to satisfy drug combination rules would not seem to be complete as at the last presentation date (Oct 2017), and if you are correct about it requiring an announcement it would seem it is not conmplete as of todays date either. I am not sure without checking if the completion of the finalised PRO for submission was subject to a reglatory announcemenet but will take your word on that. I am not on terra firma, as this is technical but it would seem logical to assume that RP is on top of this issue, hence it inclusion under Key Considerations in the last presentation. I think you are questioning their competency which I guess is not unreasoable given the track record. The dealy has been casued by the need to complete what RP presentation refers to a 008 Clinical Study. I am still confused as to why the Nov 2016 presentation refers to a new can size in the presentation when RP had previously confirmed that on the back of market research that a 20 dose can was the optimum size. In any event the 0008 study has made this a somewhat irrelevant, with the 0008 study providing allowing for a smaller presentation.

Trust it was a large Supersonic and wish I could balme my hopeless typo's on the same ! I think the Urology was doomed anyway and company being crushed under a debt mountain. JM was only ever interested in the PE drug.

Do you remember this one Bignose back in 2014 - wonder what happened to the six ? Plethora in License Talks For Drug to Rival Viagra Sales Makiko Kitamura 28 November 2014, 16:25 WET Updated on 28 November 2014, 17:20 WET Plethora Solutions Holdings Plc expects offers from at least six pharmaceutical companies to license a drug in the U.S. for premature ejaculation, according to the company founder, who helped develop and market Pfizer Inc.�s Viagra.

Alq- what evidence do you have that it is (1)still an issues and (2) if so, that appears to be unresolved?

Maybe , but given that the EMA were happy, odds are probably in RP 's favour. Now time for a special edition Super Bock ! Been a long week.

Alq- I meant what I said PE-008, but if that is incorrect it is down to RP presentation being incorrect. I don't have that detailed level of knowledge. RP are guiding Part 2 (pivotal part, I assume) clinical readout Q2 2019, later that your Q1 with FDA approval q4 2019, so huge difference there between your timeframe and RP's. Last paragrapgh , no idea what you are talking about.

Dougie- no problem - the PRO 008 is in two parts - part 2 not due until early 2019, so unfortunately not a year early !

I hope that if there is corporate activity it will come well before the FDA approval is in the bag, partuclalrly if EU sales are decent. Always good to get a gripe of your nose!

Nov 2014- seems to mew they cuaght out with their pants down as to the scope and time frame for FDA approval. Incompotence or unavoidable - pays your money takes your choice.Prabably a bit of both. This release does refer to a new can size ! It also plans to clarify and confirm the time-lines expected for the new drug application filing and potential approval of the product in the US. It expects to complete filing of the new drug application including the new can size in the fourth quarter of 2015 or first quarter of 2016. Following filing, it expects a 10 month prescription drug user fee act review, with commercial launch in the US expected for 2017.

Some will also think the apparent lack of interest in Summ's C-diff drug is insane, but then we live in a world of insanity.